Trecondi
treosulfan
Table of contents
Overview
Trecondi is a medicine given to patients before they have a bone marrow transplant from a donor known as ‘allogeneic haematopoietic stem cell transplantation’. It is used as a ‘conditioning’ treatment to clear the patient’s bone marrow and make room for the transplanted bone marrow cells, which can then produce healthy blood cells.
Trecondi is used together with a medicine called fludarabine in adults and children from 1 month of age with blood cancers or other severe disorders requiring a bone marrow transplant.
The active substance in Trecondi is treosulfan.
Haematopoietic stem cell transplantation is rare, and Trecondi was designated an ‘orphan medicine’ (a medicine used in rare diseases) on 23 February 2004.
-
List item
Trecondi : EPAR - Medicine overview (PDF/119.86 KB)
First published: 22/07/2019
Last updated: 08/08/2023
EMA/887197/2018 -
-
List item
Trecondi : EPAR - Risk-management-plan summary (PDF/102.21 KB)
First published: 22/07/2019
Last updated: 08/08/2023
Authorisation details
Product details | |
---|---|
Name |
Trecondi
|
Agency product number |
EMEA/H/C/004751
|
Active substance |
Treosulfan
|
International non-proprietary name (INN) or common name |
treosulfan
|
Therapeutic area (MeSH) |
Hematopoietic Stem Cell Transplantation
|
Anatomical therapeutic chemical (ATC) code |
L01AB02
|
Publication details | |
---|---|
Marketing-authorisation holder |
medac Gesellschaft für klinische Spezialpräparate mbH
|
Revision |
4
|
Date of issue of marketing authorisation valid throughout the European Union |
20/06/2019
|
Contact address |
Theaterstrasse 6 |
Product information
06/03/2023 Trecondi - EMEA/H/C/004751 - II/0014
This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
Pharmacotherapeutic group
Antineoplastic agents
Therapeutic indication
Treosulfan in combination with fludarabine is indicated as part of conditioning treatment prior to allogeneic haematopoietic stem cell transplantation (alloHSCT) in adult patients and in paediatric patients older than one month with malignant and non-malignant diseases.